5-fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers

被引:206
作者
Noordhuis, P
Holwerda, U
Van der Wilt, CL
Van Groeningen, CJ
Smid, K
Meijer, S
Pinedo, HM
Peters, GJ [1 ]
机构
[1] Vrije Univ Amsterdam Med Ctr, Dept Med Oncol, NL-1007 MB Amsterdam, Netherlands
[2] Vrije Univ Amsterdam Med Ctr, Dept Clin Chem, NL-1007 MB Amsterdam, Netherlands
[3] Vrije Univ Amsterdam Med Ctr, Dept Surg Oncol, NL-1007 MB Amsterdam, Netherlands
关键词
5-fluorouracil; 5-FU incorporation into DNA; 5-FU incorporation into RNA; human colorectal cancer; leucovorin; thymidylate synthase inhibition;
D O I
10.1093/annonc/mdh264
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The mechanism of action of 5-fluorouracil (5-FU) has been associated with inhibition of thymidylate synthase (TS) and incorporation of 5-FU into RNA and DNA, but limited data are available in human tumor tissue for the latter. We therefore measured incorporation in human tumor biopsy specimens after administration of a test dose of 5-FU alone or with leucovorin. Patients and methods: Patients received 5-FU (500 mg/m(2)) with or without high-dose leucovorin, low-dose leucovorin or 1-leucovorin, and biopsy specimens were taken after approximately 2, 24 or 48 h. Tissues were pulverized and extracted for nucleic acids. 5-FU incorporation was measured using gas chromatography/mass spectrometry after complete degradation to bases of isolated RNA and DNA. Results: Maximal incorporation into RNA (1.0 pmol/mug RNA) and DNA (127 fmol/mug DNA) of 59 and 46 biopsy specimens, respectively, was found at 24 h after 5-FU administration. Incorporation into RNA but not DNA was significantly correlated with intratumoral 5-FU levels. However, DNA incorporation was significantly correlated with the RNA incorporation. Primary tumor tissue, liver metastasis and normal mucosa did not show significant differences, while leucovorin had no effect. Neither for RNA (30 patients) nor DNA (24 patients) incorporation was a significant correlation with response to 5-FU therapy found. However, in the same group of patients, response was significantly correlated to TS inhibition (mean TS in responding and non-responding groups 45 and 231 pmol/h/mg protein, respectively; P = 0.001). Conclusions: 5-FU is incorporated at detectable levels into RNA and DNA of human tumor tissue, but no relation between the efficacy of 5-FU treatment and incorporation was found, in contrast to TS.
引用
收藏
页码:1025 / 1032
页数:8
相关论文
共 53 条
[1]  
Aherne GW, 1999, CANC DRUG DISC DEV, P409
[2]   CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer [J].
André, T ;
Louvet, C ;
Maindrault-Goebel, F ;
Couteau, C ;
Mabro, M ;
Lotz, JP ;
Gilles-Amar, V ;
Krulik, M ;
Carola, E ;
Izrael, V ;
de Gramont, A .
EUROPEAN JOURNAL OF CANCER, 1999, 35 (09) :1343-1347
[3]  
ARMSTRONG RD, 1986, J BIOL CHEM, V261, P7366
[4]   Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil [J].
Aschele, C ;
Debernardis, D ;
Bandelloni, R ;
Cascinu, S ;
Catalano, V ;
Giordani, P ;
Barni, S ;
Turci, D ;
Drudi, G ;
Lonardi, S ;
Gallo, L ;
Maley, F ;
Monfardini, S .
ANNALS OF ONCOLOGY, 2002, 13 (12) :1882-1892
[5]  
Backus HHJ, 2000, ONCOL RES, V12, P231
[6]   Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer [J].
Backus, HHJ ;
van Riel, JMGH ;
van Groeningen, CJ ;
Vos, W ;
Dukers, DF ;
Bloemena, E ;
Wouters, D ;
Pinedo, HM ;
Peters, GJ .
ANNALS OF ONCOLOGY, 2001, 12 (06) :779-785
[7]  
CARADONNA SJ, 1980, MOL PHARMACOL, V18, P513
[8]  
CARADONNA SJ, 1980, J BIOL CHEM, V255, P2293
[9]   High-dose 5-fluorouracil with uridine-diphosphoglucose rescue increases thymidylate synthase inhibition but not 5-fluorouracil incorporation into RNA in murine tumors [J].
Codacci-Pisanelli, G ;
Van der Wilt, CL ;
Smid, K ;
Noordhuis, P ;
Voorn, D ;
Pinedo, HM ;
Peters, GJ .
ONCOLOGY, 2002, 62 (04) :363-370
[10]   Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: A phase I study of the Southern Italy Cooperative Oncology Group [J].
Comella, P ;
Casaretti, R ;
De Vita, F ;
Avallone, A ;
Orditura, M ;
Petrillo, A ;
Gravina, A ;
Faranda, A ;
Comis, S ;
Comella, G ;
Catalano, G .
ANNALS OF ONCOLOGY, 1999, 10 (08) :915-921